{"product_id":"bms-marketing-mix","title":"Bristol Myers Squibb Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBristol Myers Squibb’s 4P’s reveal a product portfolio focused on specialty therapeutics, a value-based pricing approach, targeted distribution through hospitals and specialty pharmacies, and science-driven promotional tactics—this snapshot highlights strategic alignment across Product, Price, Place, and Promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Hematology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb's oncology and hematology portfolio centers on Opdivo and Revlimid, which drove roughly $18.5 billion combined revenue in 2024; by end-2025 the company added next-gen immunotherapies and cell therapies—Abecma and Breyanzi—expanding indications across solid tumors and hematologic malignancies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Disease Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb leads cardiovascular care via Eliquis, its oral anticoagulant co-developed with Pfizer, which generated about $10.8 billion worldwide revenue in 2024 and remained the gold standard for stroke prevention in non-valvular atrial fibrillation through late 2025 with ~40% market share in OACs.\u003c\/p\u003e\n\u003cp\u003eBMS is expanding into heart failure and obstructive hypertrophic cardiomyopathy with late-stage programs and partnerships, targeting a chronic cardiovascular market worth an estimated $45 billion by 2028, diversifying revenue beyond anticoagulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunology and Inflammation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBMS’s immunology and inflammation pipeline combines established biologic Orencia (abatacept) with newer small‑molecule Sotyktu (deucravacitinib) for plaque psoriasis; in 2024 Sotyktu global net sales reached about $1.1B while Orencia declined ~8% as biosimilars pressure older products.\u003c\/p\u003e\n\u003cp\u003eThe mix targets autoimmune disorders with biologics and selective TYK2\/JAK pathway inhibitors, aiming for higher precision and lower adverse events; R\u0026amp;D spend for immunology was roughly $2.2B in 2024, supporting next‑gen assets.\u003c\/p\u003e\n\u003cp\u003eThis segment is strategic for long‑term growth as key legacy patents expire through 2026–2028, so immunology revenue must scale to offset projected generic\/biosimilar erosion of ~$1.3B annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Cell and Gene Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb has invested \u0026gt;$15B since 2018 in CAR-T platforms, positioning itself as a leader in personalized, potentially curative therapies rather than chronic care.\u003c\/p\u003e\n\u003cp\u003eThese autologous and allogeneic products need specialized GMP manufacturing, cold-chain handling, and site-of-care accreditation, raising per-patient costs to ~$400k–$500k but reducing long-term relapse rates.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, CAR-Ts from BMS are standard for relapsed\/refractory large B-cell lymphoma and multiple myeloma, with real-world uptake reaching ~45% of eligible patients and projected revenue of $2.1B in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$15B+ invested since 2018\u003c\/li\u003e\n\u003cli\u003e$400k–$500k per patient\u003c\/li\u003e\n\u003cli\u003e45% real-world uptake by 2025\u003c\/li\u003e\n\u003cli\u003e$2.1B projected 2025 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpbristol myers squibb mid-to-late-stage pipeline centers on neurology and fibrotic indications accounting for an estimated of r value in with several phase iii assets this offsets patent expiries that exposed revenue to generic risk. bms uses ai platforms candidate discovery time by cutting trial site selection costs a steady flow high-value candidates replace aging brands.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePipeline value: ~40% neurology\/fibrosis (2025 estimate)\u003c\/li\u003e\n\u003cli\u003eRevenue at risk from expiries: ~$6.2B (2024)\u003c\/li\u003e\n\u003cli\u003eAI\/ML impact: ~30% faster discovery\u003c\/li\u003e\n\u003cli\u003eStrategy: replace aging brands with mid\/late-stage assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbristol\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS: Oncology \u0026amp; cardiology powerhouses; heavy CAR‑T bets and immunology R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBMS product mix centers on oncology (Opdivo, Revlimid; $18.5B combined 2024), cardiology (Eliquis $10.8B 2024, ~40% OAC share), immunology (Sotyktu $1.1B 2024; Orencia decline), and CAR-Ts ($2.1B 2025; $400k–$500k per patient); pipeline value ~40% neurology\/fibrosis (2025); R\u0026amp;D immunology $2.2B (2024); $15B+ CAR-T investment since 2018.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e$18.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003e$10.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSotyktu\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR-Ts\u003c\/td\u003e\n\u003ctd\u003e$2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Bristol Myers Squibb’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Bristol Myers Squibb's 4P insights into a concise, leadership-ready snapshot that clarifies product, price, place, and promotion strategies to accelerate decision-making and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb ships medicines to over 100 countries via an extensive global distribution network; in 2025 the company reported supply-chain investments of $1.1 billion to support manufacturing and logistics. The firm combines 40+ internal manufacturing sites with strategic contract manufacturing organizations to secure capacity, and it has scaled cold-chain logistics—70% of biologics and all cell therapies require temperature-controlled transport—to meet strict regulatory and quality standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy and Wholesale Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Bristol Myers Squibb products flow through large pharmaceutical wholesalers (AmerisourceBergen, McKesson, Cardinal Health) and specialty pharmacies that handle cold chain and limited‑distribution drugs; these partners managed over 70% of BMS channel shipments in 2024. They control inventory and expedite high‑cost oncology and immunology drugs to 7,500+ US hospitals and clinics. By 2025 BMS tightened SLAs and hub services, cutting median patient access time for time‑sensitive therapies by ~15%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect placement in major medical centers and oncology clinics is central to Bristol Myers Squibb’s distribution, with 68% of its 2024 oncology revenue routed through hospital-administered channels, reflecting IV and supervised-use drugs.\u003c\/p\u003e\n\u003cp\u003ePoint-of-sale is typically the healthcare facility, so BMS coordinates closely with hospital formularies and procurement teams; the company reported 12% year-over-year growth in hospital channel sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and E-Commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb (BMS) uses regulated digital ordering platforms for healthcare providers to place and track prescriptions and clinic inventory, integrating real-time utilization data to optimize replenishment and reduce shortages.\u003c\/p\u003e\n\u003cp\u003eIn 2025 BMS reported supply-chain tech investments of $150M and platform-driven stockout reductions of 18% in key markets, helping prioritize distribution of high-demand oncology and immunology therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time tracking across markets\u003c\/li\u003e\n\u003cli\u003e18% reduction in stockouts (2025)\u003c\/li\u003e\n\u003cli\u003e$150M supply-chain tech spend (2025)\u003c\/li\u003e\n\u003cli\u003ePrioritizes oncology\/immunology demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Regional Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe company keeps regional hqs and distribution hubs in north america europe asia to manage local regs shorten approval timelines bms operated major supporting revenue\u003e\n\u003cplocal hubs let bms adapt logistics and legal compliance for emerging markets cutting delivery lead times by up to improving crisis response.\u003e\n\u003cpby localizing parts of the supply chain bms raised regional inventory resilience faster allocation during health shocks and smoothing revenue volatility.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7 major regional hubs\u003c\/li\u003e\n\u003cli\u003e$46.4B global revenue (2024)\u003c\/li\u003e\n\u003cli\u003e~25% faster delivery in select regions\u003c\/li\u003e\n\u003cli\u003eImproved crisis allocation 2020–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\u003c\/plocal\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS: $46.4B revenue, 7 hubs \u0026amp; 40+ plants; $1.1B supply chain with $150M tech cut stockouts 18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBMS runs 7 regional hubs and 40+ plants, serving 100+ countries; 2025 supply‑chain spend $1.1B with $150M on tech, cutting stockouts 18% and patient access time ~15%; 68% of 2024 oncology revenue routed via hospitals; 2024 revenue $46.4B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional hubs\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlants\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$46.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 supply‑chain spend\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 tech spend\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction (2025)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology via hospitals (2024)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eBristol Myers Squibb 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Bristol Myers Squibb 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready for use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750282244473,"sku":"bms-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bms-marketing-mix.png?v=1772223936","url":"https:\/\/matrixbcg.com\/products\/bms-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}